Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer... by Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, Yasutaka Watanabe, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura

“…Cancers can develop resistance to treatment with ALK tyrosine kinase inhibitors (ALK‐TKIs) via emergence of a subpopulation of drug‐tolerant persister (DTP) cells that can survive initial drug treatment long enough to acquire genetic aberrations. …”
Get full text

Non-classical pulmonary exacerbation in cystic fibrosis revealing ALK-Translocated lung cancer: A case report by Mohamad Hadhud, Johnathan Arnon, Anat Hershko-Moshe, Adi Hollander, Noa Hurvitz-Lehmann, Assaf Potruch, Henny Azmanov, Rottem Kuint, Nurith Hiller, Elie Picard, Naama Sebbag-Sznajder, Shira Leebhoff, Michael Wilschanski, Myriam Grunewald, Liron Birimberg-Schwartz, Malena Cohen-Cymberknoh

“…Following treatment with a targeted tyrosine kinase inhibitor (TKI) there was a rapid tumor regression, however, his dyspnea and hypoxemia subsequently worsened. …”
Get full text

Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia by Neetu Pandey, Geeta Yadav, Rashmi Kushwaha, Shailendra Prasad Verma, Uma Shankar Singh, Ashutosh Kumar, Prabhaker Mishra

“…Imatinib inhibits BCR-ABL tyrosine kinase produced due to reciprocal translocation t(9;22) in neoplastic CML cells. …”
Get full text

VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+T cells function in the HCC microenvironment by Cheng Cheng, Qingrui Zha, Linmao Sun, Tianming Cui, Xinyu Guo, Changjian Xing, Zhengxiang Chen, Changyong Ji, Shuhang Liang, Shengwei Tao, Junhui Chu, Chenghui Wu, Qi Chu, Xuetian Gu, Ning Zhang, Yumin Fu, Shumin Deng, Yitong Zhu, Jiabei Wang, Yao Liu, Lianxin Liu

“…The accumulated G3P diffuses into the TME and directly interacts with SRC-family tyrosine kinase LCK, a critical component of the T-cell receptor (TCR) signaling pathway in CD8+T cells. …”
Get full text

Exploring precision therapeutics: computational design of antisense oligonucleotides targeting AXL gene transcripts in multiple sclerosis treatment management by Bhargav Shreevatsa, Bhargav Shreevatsa, Abhigna Nagaraj, Chandan Dharmashekar, Anisha Jain, Bhavana Harendra, Siddesh V. Siddalingegowda, Haneen A. Al-Mazroua, Sheikh F. Ahmad, Shashanka K. Prasad, Chandrashekar Srinivasa, Chandan Shivamallu, Shiva Prasad Kollur

“…The AXL gene, which codes for a receptor tyrosine kinase, has emerged as a promising therapeutic target due to its involvement in neuroinflammation and oligodendrocyte dysfunction. …”
Get full text

Gene Expression Pattern and Regulatory Network of α-Toxin Treatment in Bombyx mori by Tieshan Feng, Ping Lin, Jiao Gong, Dong Cheng, Xi Yang, Quan Zhang, Tingcai Cheng

“…The upregulated genes in the midgut were mainly involved in peptidoglycan catabolic process and tyrosine kinase signaling pathway, whereas the downregulated genes were mainly involved in chitin metabolic pathways. …”
Get full text

Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages by Yuan Li, Yanping Chen, Yuan Meng, Meng Shen, Fan Yang, Xiubao Ren

“…Objective: The combination of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) leads to an increased incidence of severe immune-related adverse events (irAEs). …”
Get full text

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort by Hilin Yildirim, Anke Richters, Adriaan D. Bins, Arnoud W. Postema, Maureen J.B. Aarts, Martijn G.H. van Oijen, Patricia J. Zondervan, Katja K.H. Aben

“…Targeted therapy with tyrosine kinase inhibitors (TKIs) was the standard of care for metastatic renal cell carcinoma (mRCC) until recently, when new first-line combinations with immuno-oncology (IO) agents were approved. …”
Get full text

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation by Chang Dong Yeo, Dong Won Park, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, Chang‐Min Choi, In‐Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young‐Chul Kim, Tae Won Jang, Kye Young Lee, Seung Hun Jang, Seung Joon Kim, for the Korean EGFR Registry Investigators

“…Moreover, it will investigate various aspects, including the safety and efficacy of a new third‐generation EGFR tyrosine kinase inhibitor (TKI), lazertinib, approved for both first‐ and second‐line treatments. …”
Get full text

Role of the Btk-PLCγ2 Signaling Pathway in the Bone Destruction of Apical Periodontitis by Lina Wang, Hong Zhang, Ming Dong, Meina Zuo, Shuo Liu, Ying Lu, Weidong Niu

“…Studies have shown that the Bruton tyrosine kinase- (Btk-) phospholipase Cγ2 (PLCγ2) signaling pathway plays an important role in bone absorption, but it is unknown whether it plays a role in apical periodontitis bone destruction. …”
Get full text

Cross-Talk between NOK and EGFR: Juxtamembrane and Kinase domain interactions enhancing STAT3/5 signaling in breast cancer tumorigenesis by Yinyin Wang, Bingdong Zhang, Chunhua He, Bo Tian, Sihan Liu, Jianghua Li, Jiayu Wang, Shigao Yang, Bingtao Zhu, Xiaoguang Wang, Zhijie Chang, Chenxi Cao

“…Here we report that NOK (also known as STYK1), a novel tyrosine kinase cross-talks with EGFR to promote tumorigenesis and metastasis of breast cancer cells. …”
Get full text

Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients by Umberto Basile, Mariapaola Marino, Cecilia Napodano, Krizia Pocino, Paolo Emilio Alboini, Francesca Gulli, Amelia Evoli, Carlo Provenzano, Emanuela Bartoccioni

“…Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction with antibodies (abs) targeting the acetylcholine receptor (AChR) or the muscle-specific tyrosine kinase (MuSK), inducing muscle weakness and excessive fatigability. …”
Get full text

Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma by Yaya Chu, Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose, Alyssa S. Mendelowitz, Keira Foley, Mehmet F. Ozkaynak, Wen Luo, Timothy P. Cripe, Dean A. Lee, Kevin A. Cassady, Mitchell S. Cairo

“…Novel therapies are desperately needed. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is highly expressed on NB. …”
Get full text

Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia by Qi Zhou, Yongyu Guan, Pingping Zhao, Huiyuan Chu, Yaming Xi

“…Gilteritinib treats acute myeloid leukemia (AML) with the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. …”
Get full text

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY by Jill Feldman, MA, Ivy Elkins, MBA, Zofia Piotrowska, MD, Bellinda L. King-Kallimanis, PhD, Tendai Chihuri, MD, Carly Johnson, BS, Alecia Clary, PhD, Teri Kennedy, MA, Upal Basu Roy, PhD, MPH

“…In addition, 89% reported receiving at least one tyrosine kinase inhibitor (TKI); osimertinib was the most prescribed first-line TKI for stage IV participants diagnosed after 2017. …”
Get full text

Nicotine is associated with smoking dependence and vascular inflammation through cotinine: A mediation analysis by Kumboyono Kumboyono, Indah N. Chomsy, Nadya N. Shalshabilla, Hidayat Sujuti, Arie Srihardyastutie, Cholid T. Tjahjono, Teuku Heriansyah, Titin A. Wihastuti

“…This study aimed to evaluate the relationship between NO levels and cotinine through the expression of nAChRs that mediate the nicotine dependence mechanism and Tie2 (Tyrosine Kinase 2) expression. Methods A cross-sectional study was conducted with 200 participants grouped into two groups based on their smoking status: 100 smokers and 100 non-smokers. …”
Get full text

Comparison of tissue-based and plasma-based testing for mutation in non–small cell lung cancer patients by Yoon Kyung Kang, Dong Hoon Shin, Joon Young Park, Chung Su Hwang, Hyun Jung Lee, Jung Hee Lee, Jee Yeon Kim, JooYoung Na

“…Background Epidermal growth factor receptor (EGFR) gene mutation testing is crucial for the administration of tyrosine kinase inhibitors to treat non–small cell lung cancer. …”
Get full text

Ewing sarcoma – pathomechanisms, standard treatment and new therapeutic perspectives by Wojciech Zezuliński, Filip Woliński, Julia Zyśk, Mateusz Korga, Jakub Klas, Jacek Baj, Eliasz Dzierżyński

“…The paper discusses, among other things, treatment attempts based on the role of the EWS-FLI1 protein, epigenetics, tyrosine kinase inhibitors, immunotherapies and the use of nanomedicine and viruses, as well as the difficulties associated with their application. …”
Get full text

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy by Meng-Tung Hsu, Gerald Willimsky, Gerald Willimsky, Gerald Willimsky, Leo Hansmann, Leo Hansmann, Leo Hansmann, Leo Hansmann, Thomas Blankenstein

“…BCR-ABL kinase is the major oncogenic driver of chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs), which are highly potent in targeting BCR-ABL, are currently used as first-line treatment. …”
Get full text

The dilemma of X-linked agammaglobulinemia carriers by Federica Pulvirenti, MD, PhD, Cinzia Milito, MD, PhD, Francesco Cinetto, MD, PhD, Giulia Garzi, MD, Germano Sardella, MD, Giuseppe Spadaro, MD, Francesca Lippi, MD, Valentina Guarnieri, MD, Bianca Laura Cinicola, MD, Maria Carrabba, MD, PhD, Daniele Guadagnolo, MD, Giovanna Fabio, MD, Baldassarre Martire, MD, Caterina Cancrini, MD, PhD, Giulia Lanzoni, MD, Andrea Finocchi, MD, PhD, Gigliola Di Matteo, MD, PhD, Eva Pompilii, MD, Simona Ferrari, BD, PhD, Isabella Quinti, MD, PhD

“…Background: Many patients with X-linked agammaglobulinemia (XLA) nowadays have reached adulthood, as well as their sisters, possibly carriers of a deleterious Bruton tyrosine kinase variant. Studies on motherhood outcomes in families with XLA are lacking. …”
Get full text